All In Biotech

Drug Trial Radar · NCT06444763

Effect of Maolactin™ FMR on Exercise Recovery, Inflammation and Muscle Comfort in an Otherwise Healthy Population

Effect of Maolactin™ FMR Supplementation on Exercise Recovery, Inflammation, and Muscle Comfort in an Otherwise Healthy Population: A Double-blind Randomized Placebo-controlled Study

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

97

Actual

Start

Feb 27, 2025

Primary completion

Feb 16, 2026

Study completion Feb 16, 2026

Sponsor

Lead sponsor
RDC Clinical Pty LtdIndustry
Sponsor type
Industry
First posted
Jun 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a double blind, randomised, placebo-controlled, parallel-group trial to evaluate the effect of Maolactin FMR supplementation on chronic inflammation, mobility and muscle and joint pain in an otherwise healthy population of adults over 45 years old over 10 weeks with 8 weeks supplementation. This is PART B of the study.

Conditions

  • Chronic Inflammation
  • Mobility
  • Muscle Pain
  • Joint Pain

Interventions

  • MaolactinDrug

    Once daily dose of 2 capsules containing a total of 500mg/day Maolactin

  • MaltodextrinDrug

    Once daily dose of 2 capsules of Maltodextrin containing a total of 0mg/day Maolactin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Inflammatory statusTime frame: Baseline and Week 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • RDC Clinical Pty Ltd

    Brisbane, Queensland, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.